Symbols / OSTX Stock $1.27 -6.62% OS Therapies Incorporated
OSTX (Stock) Chart
About
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 48.21M |
| Enterprise Value | 51.27M | Income | -28.75M | Sales | — |
| Book/sh | -0.16 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -8.11 | PEG | — |
| P/S | — | P/B | -7.74 | P/C | — |
| EV/EBITDA | -1.81 | EV/Sales | — | Quick Ratio | 0.02 |
| Current Ratio | 0.03 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.98 | EPS next Y | -0.16 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-14 | ROA | -289.88% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 37.96M |
| Shs Float | 28.33M | Short Float | 3.74% | Short Ratio | 3.46 |
| Short Interest | — | 52W High | 2.57 | 52W Low | 1.12 |
| Beta | — | Avg Volume | 579.69K | Volume | 791.93K |
| Target Price | $10.89 | Recom | Strong_buy | Prev Close | $1.36 |
| Price | $1.27 | Change | -6.62% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.89
Mean price target
2. Current target
$1.27
Latest analyst target
3. DCF / Fair value
$-4.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.27
Low
$6.00
High
$20.00
Mean
$10.89
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-27 | main | D. Boral Capital | Buy → Buy | $20 |
| 2026-03-09 | main | D. Boral Capital | Buy → Buy | $20 |
| 2026-02-05 | main | D. Boral Capital | Buy → Buy | $20 |
| 2026-01-05 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-12-15 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-12-09 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-12-05 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-11-21 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-11-18 | main | Lake Street | Buy → Buy | $17 |
| 2025-11-17 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-10-10 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-09-30 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-09-12 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-09-02 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-08-27 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-08-20 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-08-07 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-07-14 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-07-03 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-06-30 | main | D. Boral Capital | Buy → Buy | $20 |
- OS Therapies says $5.25M raise and UK tax refunds fund runway into 2027 - Stock Titan hu, 02 Apr 2026 21
- OSTX Technical Analysis & Stock Price Forecast - Intellectia AI Wed, 01 Apr 2026 22
- OSTX Surges 11% Pre-Market with No Clear Catalyst - Bitget Wed, 01 Apr 2026 21
- OS Therapies Incorporated (OSTX) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade hu, 02 Apr 2026 00
- OS Therapies bolsters funding to advance OST-HER2 program - TipRanks hu, 02 Apr 2026 22
- D. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSEAMERICAN:OSTX) - MarketBeat Mon, 09 Mar 2026 07
- OS Therapies (OSTX) nets $4.7M, eyes extra $4M non-dilutive funding - Stock Titan hu, 02 Apr 2026 21
- OS Therapies (NYSE: OSTX) offers 2.5M shares with detachable warrants, raising ~$4.7M - Stock Titan hu, 02 Apr 2026 21
- FDA meeting shift puts OS Therapies cancer shot on $205M voucher path - Stock Titan Mon, 09 Mar 2026 07
- Cancer drug data heads to FDA as OS Therapies targets 2H26 approval - Stock Titan ue, 31 Mar 2026 11
- Rare bone cancer therapy gains faster EU path after EMA designation - Stock Titan Wed, 25 Mar 2026 07
- OS Therapies (NYSE: OSTX) details resale of 10,529,417 shares and legal opinion - Stock Titan ue, 31 Mar 2026 20
- A rare bone cancer trial moves closer as 4 regulators schedule reviews - Stock Titan Fri, 27 Mar 2026 07
- New law extends FDA voucher chance for OS Therapies’ childhood cancer drug - Stock Titan Wed, 04 Feb 2026 08
- Rare bone-cancer drug seeks FDA shortcut and voucher last sold for $200M - Stock Titan ue, 17 Feb 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
28.71
+321.28%
|
6.81
+56.91%
|
4.34
-2.33%
|
4.45
|
| Research And Development |
|
16.36
+476.27%
|
2.84
-11.75%
|
3.22
-2.26%
|
3.29
|
| Selling General And Administration |
|
12.34
+210.58%
|
3.97
+253.09%
|
1.13
-2.42%
|
1.15
|
| General And Administrative Expense |
|
12.34
+210.58%
|
3.97
+253.09%
|
1.13
-2.42%
|
1.15
|
| Other Gand A |
|
12.34
+210.58%
|
3.97
+253.09%
|
1.13
-2.42%
|
1.15
|
| Other Operating Expenses |
|
—
|
—
|
0.01
+325.95%
|
0.00
|
| Total Expenses |
|
28.71
+321.28%
|
6.81
+56.91%
|
4.34
-2.33%
|
4.45
|
| Operating Income |
|
-28.71
-321.28%
|
-6.81
-56.91%
|
-4.34
+2.33%
|
-4.45
|
| Total Operating Income As Reported |
|
-28.71
-321.28%
|
-6.81
-56.91%
|
-4.34
+2.33%
|
-4.45
|
| EBITDA |
|
-28.39
-315.78%
|
-6.83
-57.39%
|
-4.34
+2.41%
|
-4.45
|
| Normalized EBITDA |
|
-29.82
-336.64%
|
-6.83
-57.39%
|
-4.34
+2.41%
|
-4.45
|
| Reconciled Depreciation |
|
0.36
+12960.61%
|
0.00
-34.12%
|
0.00
+424.22%
|
0.00
|
| EBIT |
|
-28.75
-320.93%
|
-6.83
-57.30%
|
-4.34
+2.33%
|
-4.45
|
| Total Unusual Items |
|
1.42
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
1.42
|
—
|
—
|
—
|
| Net Income |
|
-28.75
-223.70%
|
-8.88
-14.01%
|
-7.79
-24.57%
|
-6.25
|
| Pretax Income |
|
-28.75
-223.70%
|
-8.88
-14.01%
|
-7.79
-24.57%
|
-6.25
|
| Net Non Operating Interest Income Expense |
|
0.00
+100.01%
|
-2.05
+40.51%
|
-3.45
-90.72%
|
-1.81
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
2.05
-40.51%
|
3.45
+90.72%
|
1.81
|
| Net Interest Income |
|
0.00
+100.01%
|
-2.05
+40.51%
|
-3.45
-90.72%
|
-1.81
|
| Interest Expense |
|
0.00
-100.00%
|
2.05
-40.51%
|
3.45
+90.72%
|
1.81
|
| Interest Income Non Operating |
|
0.00
|
0.00
-100.00%
|
0.00
|
0.00
|
| Interest Income |
|
0.00
|
0.00
-100.00%
|
0.00
|
0.00
|
| Other Income Expense |
|
-0.05
-180.48%
|
-0.02
|
—
|
—
|
| Other Non Operating Income Expenses |
|
-1.47
-8437.62%
|
-0.02
|
—
|
—
|
| Gain On Sale Of Security |
|
1.42
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-28.75
-223.70%
|
-8.88
-14.01%
|
-7.79
-24.57%
|
-6.25
|
| Net Income From Continuing Operation Net Minority Interest |
|
-28.75
-223.70%
|
-8.88
-14.01%
|
-7.79
-24.57%
|
-6.25
|
| Net Income From Continuing And Discontinued Operation |
|
-28.75
-223.70%
|
-8.88
-14.01%
|
-7.79
-24.57%
|
-6.25
|
| Net Income Continuous Operations |
|
-28.75
-223.70%
|
-8.88
-14.01%
|
-7.79
-24.57%
|
-6.25
|
| Normalized Income |
|
-30.18
-239.73%
|
-8.88
-14.01%
|
-7.79
-24.57%
|
-6.25
|
| Net Income Common Stockholders |
|
-28.75
-222.56%
|
-8.91
-12.60%
|
-7.92
-24.09%
|
-6.38
|
| Diluted EPS |
|
—
|
-1.28
-233.04%
|
-0.38
-20.79%
|
-0.32
|
| Basic EPS |
|
—
|
-1.28
-233.04%
|
-0.38
-20.79%
|
-0.32
|
| Basic Average Shares |
|
—
|
6.95
-66.26%
|
20.60
+2.73%
|
20.05
|
| Diluted Average Shares |
|
—
|
6.95
-66.26%
|
20.60
+2.73%
|
20.05
|
| Diluted NI Availto Com Stockholders |
|
-28.75
-222.56%
|
-8.91
-12.60%
|
-7.92
-24.09%
|
-6.38
|
| Preferred Stock Dividends |
|
—
|
0.03
-75.00%
|
0.12
+0.00%
|
0.12
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
6.84
+23.48%
|
5.54
+594.01%
|
0.80
+56.76%
|
0.51
|
| Current Assets |
|
0.33
-93.98%
|
5.53
+600.42%
|
0.79
+59.01%
|
0.50
|
| Cash Cash Equivalents And Short Term Investments |
|
0.27
-95.12%
|
5.53
+14095.08%
|
0.04
-77.27%
|
0.17
|
| Cash And Cash Equivalents |
|
0.27
-95.12%
|
5.53
+14095.08%
|
0.04
-77.27%
|
0.17
|
| Cash Financial |
|
0.27
-95.12%
|
5.53
+14095.08%
|
0.04
-77.27%
|
0.17
|
| Receivables |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Loans Receivable |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Prepaid Assets |
|
0.06
|
0.00
|
—
|
0.00
|
| Current Deferred Assets |
|
—
|
0.00
-100.00%
|
0.75
+131.66%
|
0.32
|
| Total Non Current Assets |
|
6.51
+123365.31%
|
0.01
-34.53%
|
0.01
-34.39%
|
0.01
|
| Net PPE |
|
0.00
-52.75%
|
0.01
-34.53%
|
0.01
-34.39%
|
0.01
|
| Goodwill And Other Intangible Assets |
|
6.50
|
0.00
|
—
|
—
|
| Other Intangible Assets |
|
6.50
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
12.94
+46.90%
|
8.81
-64.52%
|
24.81
+37.35%
|
18.07
|
| Current Liabilities |
|
11.76
+154.24%
|
4.63
-81.28%
|
24.71
+302.00%
|
6.15
|
| Payables And Accrued Expenses |
|
11.76
+343.05%
|
2.66
-50.77%
|
5.39
+73.50%
|
3.11
|
| Payables |
|
10.31
+406.19%
|
2.04
-33.41%
|
3.06
+111.87%
|
1.44
|
| Accounts Payable |
|
9.94
+497.83%
|
1.66
-38.79%
|
2.72
+121.64%
|
1.23
|
| Dividends Payable |
|
0.38
+0.00%
|
0.38
+9.09%
|
0.34
+57.14%
|
0.22
|
| Current Accrued Expenses |
|
1.45
+135.02%
|
0.62
-73.52%
|
2.33
+40.22%
|
1.66
|
| Total Tax Payable |
|
—
|
—
|
—
|
0.43
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
14.61
|
—
|
| Current Debt |
|
—
|
—
|
14.61
|
—
|
| Other Current Borrowings |
|
—
|
—
|
14.61
|
—
|
| Other Current Liabilities |
|
—
|
1.97
-58.13%
|
4.71
+54.99%
|
3.04
|
| Total Non Current Liabilities Net Minority Interest |
|
1.17
-71.98%
|
4.18
+4078.03%
|
0.10
-99.16%
|
11.92
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
10.35
|
| Long Term Debt |
|
—
|
—
|
—
|
10.35
|
| Non Current Deferred Liabilities |
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Non Current Deferred Revenue |
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
1.47
|
| Preferred Securities Outside Stock Equity |
|
1.07
-73.74%
|
4.08
|
0.00
|
—
|
| Stockholders Equity |
|
-6.10
-86.61%
|
-3.27
+86.40%
|
-24.02
-36.79%
|
-17.56
|
| Common Stock Equity |
|
-6.10
-86.61%
|
-3.27
+86.40%
|
-24.02
-36.79%
|
-17.56
|
| Capital Stock |
|
0.04
+77.84%
|
0.02
+214.21%
|
0.01
+5.56%
|
0.01
|
| Common Stock |
|
0.04
+77.84%
|
0.02
+290.82%
|
0.01
+7.01%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Share Issued |
|
37.11
+77.83%
|
20.87
+1.32%
|
20.60
+0.00%
|
20.60
|
| Ordinary Shares Number |
|
37.11
+77.83%
|
20.87
+1.32%
|
20.60
+0.00%
|
20.60
|
| Additional Paid In Capital |
|
61.05
+73.72%
|
35.14
+539.54%
|
5.50
+36.09%
|
4.04
|
| Retained Earnings |
|
-67.19
-74.82%
|
-38.43
-30.20%
|
-29.52
-36.65%
|
-21.60
|
| Total Equity Gross Minority Interest |
|
-6.10
-86.61%
|
-3.27
+86.40%
|
-24.02
-36.79%
|
-17.56
|
| Total Capitalization |
|
-6.10
-86.61%
|
-3.27
+86.40%
|
-24.02
-233.11%
|
-7.21
|
| Working Capital |
|
-11.43
-1361.46%
|
0.91
+103.79%
|
-23.92
-323.37%
|
-5.65
|
| Invested Capital |
|
-6.10
-86.61%
|
-3.27
+65.28%
|
-9.41
-30.46%
|
-7.21
|
| Total Debt |
|
—
|
—
|
14.61
+41.20%
|
10.35
|
| Net Debt |
|
—
|
—
|
14.57
+43.19%
|
10.18
|
| Net Tangible Assets |
|
-12.60
-285.72%
|
-3.27
+86.40%
|
-24.02
-36.79%
|
-17.56
|
| Tangible Book Value |
|
-12.60
-285.72%
|
-3.27
+86.40%
|
-24.02
-36.79%
|
-17.56
|
| Interest Payable |
|
—
|
0.00
-100.00%
|
2.03
+65.57%
|
1.22
|
| Preferred Stock Equity |
|
—
|
6.05
+464569.74%
|
0.00
+0.00%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-14.24
-95.52%
|
-7.28
-142.18%
|
-3.01
+20.71%
|
-3.79
|
| Cash Flow From Continuing Operating Activities |
|
-14.24
-95.52%
|
-7.28
-142.18%
|
-3.01
+20.71%
|
-3.79
|
| Net Income From Continuing Operations |
|
-28.75
-223.70%
|
-8.88
-14.01%
|
-7.79
-24.57%
|
-6.25
|
| Depreciation Amortization Depletion |
|
0.36
+12960.61%
|
0.00
-34.12%
|
0.00
+424.22%
|
0.00
|
| Depreciation |
|
0.36
+12960.61%
|
0.00
-34.12%
|
0.00
+424.22%
|
0.00
|
| Depreciation And Amortization |
|
0.36
+12960.61%
|
0.00
-34.12%
|
0.00
+424.22%
|
0.00
|
| Other Non Cash Items |
|
1.61
+10.05%
|
1.46
-47.19%
|
2.76
+82.51%
|
1.51
|
| Stock Based Compensation |
|
4.86
+1712.08%
|
0.27
|
0.00
|
—
|
| Operating Gains Losses |
|
-1.42
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-1.42
|
—
|
—
|
—
|
| Change In Working Capital |
|
9.11
+7126.53%
|
-0.13
-106.43%
|
2.02
+112.94%
|
0.95
|
| Change In Payables And Accrued Expense |
|
9.11
+7126.53%
|
-0.13
-106.43%
|
2.02
+112.94%
|
0.95
|
| Change In Accrued Expense |
|
0.83
-9.62%
|
0.92
+37.94%
|
0.67
-8.38%
|
0.73
|
| Change In Payable |
|
8.27
+885.54%
|
-1.05
-178.16%
|
1.35
+522.66%
|
0.22
|
| Change In Account Payable |
|
8.27
+885.54%
|
-1.05
-178.16%
|
1.35
+522.66%
|
0.22
|
| Investing Cash Flow |
|
-0.47
|
0.00
-100.00%
|
0.00
-99.50%
|
0.23
|
| Cash Flow From Continuing Investing Activities |
|
-0.47
|
0.00
-100.00%
|
0.00
-99.50%
|
0.23
|
| Net PPE Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
-0.47
|
—
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
-0.47
|
0.00
|
—
|
—
|
| Purchase Of Intangibles |
|
-0.47
|
0.00
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
0.00
-99.50%
|
0.23
|
| Financing Cash Flow |
|
9.44
-26.11%
|
12.78
+344.67%
|
2.87
-21.33%
|
3.65
|
| Cash Flow From Continuing Financing Activities |
|
9.44
-26.11%
|
12.78
+344.67%
|
2.87
-21.33%
|
3.65
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
1.50
-52.46%
|
3.16
-17.44%
|
3.82
|
| Issuance Of Debt |
|
0.00
-100.00%
|
1.75
-44.54%
|
3.16
-17.44%
|
3.82
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.25
|
0.00
|
—
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
1.50
-52.46%
|
3.16
-17.44%
|
3.82
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
1.50
-52.46%
|
3.16
-17.44%
|
3.82
|
| Short Term Debt Issuance |
|
0.00
-100.00%
|
0.25
|
0.00
|
—
|
| Short Term Debt Payments |
|
0.00
+100.00%
|
-0.25
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
0.00
|
0.00
|
0.00
|
—
|
| Net Common Stock Issuance |
|
7.86
+50.37%
|
5.23
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
0.53
|
0.00
|
—
|
—
|
| Net Other Financing Charges |
|
—
|
—
|
-0.28
-65.20%
|
-0.17
|
| Changes In Cash |
|
-5.26
-195.80%
|
5.49
+4246.89%
|
-0.13
-246.10%
|
0.09
|
| Beginning Cash Position |
|
5.53
+14095.08%
|
0.04
-77.27%
|
0.17
+112.26%
|
0.08
|
| End Cash Position |
|
0.27
-95.12%
|
5.53
+14095.08%
|
0.04
-77.27%
|
0.17
|
| Free Cash Flow |
|
-14.70
-101.93%
|
-7.28
-142.18%
|
-3.01
+20.71%
|
-3.79
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Change In Interest Payable |
|
0.00
-100.00%
|
0.61
-23.54%
|
0.80
+22.16%
|
0.66
|
| Common Stock Issuance |
|
7.86
+50.37%
|
5.23
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
8.91
-20.97%
|
11.28
|
0.00
|
—
|
| Net Preferred Stock Issuance |
|
1.05
-82.60%
|
6.05
|
0.00
|
—
|
| Preferred Stock Issuance |
|
1.05
-82.60%
|
6.05
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-02 View
- 8-K2026-03-31 View
- 10-K2026-03-31 View
- 8-K2026-03-06 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 8-K2026-02-13 View
- 8-K2026-01-12 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|